

Prostate Cancer™

U P D A T E

Conversations with Urologic Oncology Investigators
Bridging the Gap between Research and Patient Care

FACULTY INTERVIEWS

E David Crawford, MD

Christopher J Logothetis, MD

Robert Dreicer, MD, MS

Allan Lipton, MD

EDITOR

Neil Love, MD

CME
Certified



Prostate Cancer Update

A Continuing Medical Education Audio Series

OVERVIEW OF ACTIVITY

An estimated 220,000 new cases of prostate cancer are diagnosed yearly in the United States and account for approximately one third of new cancer cases among men. Published results from clinical trials lead to the emergence of new local and systemic therapeutic approaches, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. By providing information on the latest research developments and expert perspectives, this CME activity assists clinicians with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

- Develop a rational evidence-based approach to the use of bone-targeted therapies for patients with early and advanced-stage prostate cancer.
- Counsel patients with metastatic castration-resistant prostate cancer (mCRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life.
- Compare and contrast the efficacy, safety and tolerability of evidence-based chemotherapy and immunotherapy for patients with mCRPC.
- Recognize the contribution of symptoms and tumor burden in the decision to employ sipuleucel-T in the treatment of mCRPC.
- Explore the emerging data and active research evaluating novel agents — including tyrosine kinase inhibitors, radiopharmaceuticals, androgen biosynthesis inhibitors and antiandrogens — in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity.
- Recall pivotal Phase III findings with abiraterone acetate in chemotherapy-pretreated CRPC.
- Counsel appropriately selected patients with biochemically recurrent, asymptomatic or symptomatic metastatic prostate cancer about availability of and participation in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CDs, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/PCU111/CME.

This activity is supported by educational grants from Amgen Inc, Astellas Pharma Global Development Inc/ Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation and Sanofi.

Last review date: November 2011; Release date: November 2011; Expiration date: November 2012

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

If you would like to discontinue your complimentary subscription to *Prostate Cancer Update*, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

Prostate Cancer™

U P D A T E

FACULTY AFFILIATIONS



E David Crawford, MD

Professor of Surgery, Urology and Radiation Oncology
Head, Section of Urologic Oncology, University of Colorado at Denver Health Science Center
Denver, Colorado



Robert Dreicer, MD, MS

Chairman, Department of Solid Tumor Oncology
Taussig Cancer Institute
Cleveland Clinic; Professor of Medicine, Cleveland Clinic
Lerner College of Medicine
Cleveland, Ohio



Christopher J Logothetis, MD

Chairman/Professor
Genitourinary Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas



Allan Lipton, MD

Professor of Medicine and Oncology, Division of Hematology/Oncology
MS Hershey Medical Center
The Pennsylvania State University
Hershey, Pennsylvania

EDITOR



Neil Love, MD

Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Crawford** — Advisory Committee: Centocor Ortho Biotech Services LLC, Ferring, GlaxoSmithKline, Sanofi; Employee (Wife): Ferring; Meeting Participant: Aureon Laboratories Inc. **Dr Logothetis** — Paid Research: Dendreon Corporation, Johnson & Johnson Pharmaceuticals. **Dr Dreicer** — Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Centocor Ortho Biotech Services LLC, EMD Serono Inc, GTX Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi; Consulting Agreement: Centocor Ortho Biotech Services LLC. **Dr Lipton** — Advisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, Novartis Pharmaceuticals Corporation; Paid Research: Amgen Inc, Monogram Biosciences Inc, Novartis Pharmaceuticals Corporation.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

QUESTIONS (PLEASE CIRCLE ANSWER):

1. Which of the following statements is true about denosumab?
 - a. It is administered subcutaneously
 - b. It is a RANK ligand inhibitor
 - c. It prolonged time to development of bone metastasis in men with CRPC
 - d. All of the above
2. In the Phase III ALSYMPCA study, radium-223 chloride (Alpharadin®) improved overall survival for patients with CRPC and symptomatic bone metastases.
 - a. True
 - b. False
3. Immunotherapy with sipuleucel-T resulted in a significant improvement in overall survival for patients who _____.
 - a. Had chemotherapy-naïve disease
 - b. Had mCRPC
 - c. Were asymptomatic or minimally symptomatic
 - d. All of the above
4. In the TROPIC trial, men with mCRPC who experienced disease progression while receiving docetaxel did *not* experience an improvement in overall survival or progression-free survival with cabazitaxel.
 - a. True
 - b. False
5. MDV3100 is a(n) _____.
 - a. Third-generation taxane
 - b. Immunotherapeutic agent
 - c. Antiandrogen with a high affinity to the androgen receptor
6. For patients with CRPC and bone metastases, the RANK-L inhibitor denosumab was superior to zoledronic acid in the prevention of skeletal-related events.
 - a. True
 - b. False
7. Which of the following results were observed in a randomized Phase II study of cabozantinib (XL184) versus placebo in men with progressive, measurable mCRPC?
 - a. High rates of bone-scan resolution
 - b. High rates of pain relief
 - c. Both a and b
 - d. Neither a nor b
8. Treatment of advanced prostate cancer with sipuleucel-T results in a high rate of objective tumor regression.
 - a. True
 - b. False
9. Abiraterone specifically inhibits CYP17A1 and consequently blocks the synthesis of androgens and decreases testosterone in patients with prostate cancer.
 - a. True
 - b. False
10. SRC signaling, which can be inhibited by dasatinib, has been strongly implicated in prostate cancer progression in the bone.
 - a. True
 - b. False

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART ONE — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

| | 4 = Excellent | 3 = Good | 2 = Adequate | 1 = Suboptimal |
|--|---------------|----------|--------------|----------------|
| | BEFORE | | AFTER | |
| Phase III study demonstrating prolonged bone metastasis-free survival with adjuvant denosumab for CRPC | 4 | 3 | 2 | 1 |
| Interim results of the Phase III ALSYMPCA study evaluating Alpharadin in patients with symptomatic mCRPC | 4 | 3 | 2 | 1 |
| Appropriate patient selection for and the inability to measure response to sipuleucel-T | 4 | 3 | 2 | 1 |
| Preliminary clinical trial results with cabozantinib in mCRPC | 4 | 3 | 2 | 1 |
| Differences in the mechanisms of action of the androgen biosynthesis inhibitor abiraterone and MDV-3100 | 4 | 3 | 2 | 1 |

Was the activity evidence based, fair, balanced and free from commercial bias?

Yes No If no, please explain:

Please identify how you will change your practice as a result of completing this activity (select all that apply).

- This activity validated my current practice; no changes will be made
- Create/revise protocols, policies and/or procedures
- Change the management and/or treatment of my patients
- Other (please explain):

If you intend to implement any changes in your practice, please provide 1 or more examples:

The content of this activity matched my current (or potential) scope of practice.

Yes No If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Develop a rational evidence-based approach to the use of bone-targeted therapies for patients with early and advanced-stage prostate cancer. 4 3 2 1 N/M N/A
- Counsel patients with metastatic castration-resistant prostate cancer (mCRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life. 4 3 2 1 N/M N/A
- Compare and contrast the efficacy, safety and tolerability of evidence-based chemotherapy and immunotherapy for patients with mCRPC. 4 3 2 1 N/M N/A
- Recognize the contribution of symptoms and tumor burden in the decision to employ sipuleucel-T in the treatment of mCRPC. 4 3 2 1 N/M N/A
- Explore the emerging data and active research evaluating novel agents — including tyrosine kinase inhibitors, radiopharmaceuticals, androgen biosynthesis inhibitors and antiandrogens — in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity. 4 3 2 1 N/M N/A
- Recall pivotal Phase III findings with abiraterone acetate in chemotherapy-pretreated CRPC. 4 3 2 1 N/M N/A
- Counsel appropriately selected patients with biochemically recurrent, asymptomatic or symptomatic metastatic prostate cancer about availability of and participation in ongoing clinical trials. 4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

.....
Would you recommend this activity to a colleague?

Yes No

If no, please explain:

Additional comments about this activity:

.....
As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

Yes, I am willing to participate in a follow-up survey.
 No, I am not willing to participate in a follow-up survey.

PART TWO — Please tell us about the faculty and editor for this educational activity

| | 4 = Excellent | 3 = Good | 2 = Adequate | 1 = Suboptimal | |
|------------------------------|------------------------------------|----------|--------------|-------------------------------------|---------|
| Faculty | Knowledge of subject matter | | | Effectiveness as an educator | |
| E David Crawford, MD | 4 | 3 | 2 | 1 | 4 3 2 1 |
| Christopher J Logothetis, MD | 4 | 3 | 2 | 1 | 4 3 2 1 |
| Robert Dreicer, MD, MS | 4 | 3 | 2 | 1 | 4 3 2 1 |
| Allan Lipton, MD | 4 | 3 | 2 | 1 | 4 3 2 1 |
| Editor | Knowledge of subject matter | | | Effectiveness as an educator | |
| Neil Love, MD | 4 | 3 | 2 | 1 | 4 3 2 1 |

Please recommend additional faculty for future activities:

.....
Other comments about the faculty and editor for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: Specialty:

Professional Designation:

MD DO PharmD NP RN PA Other

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: Date:

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/PCU111/CME.

Prostate Cancer™

U P D A T E

| | |
|---|---|
| Editor | Neil Love, MD |
| Managing Editor and CME Director | Kathryn Ault Ziel, PhD |
| Scientific Director | Richard Kaderman, PhD |
| Editorial | Clayton Campbell Gloria Kelly, PhD Jean Pak Margaret Peng |
| Creative Manager | Fernando Rendina |
| Graphic Designers | Jessica Benitez Jason Cunniss Tamara Dabney Silvana Izquierdo Deepti Nath |
| Copy Editing Manager | Kirsten Miller |
| Senior Production Editor | Aura Herrmann |
| Copy Editors | Margo Harris David Hill Rosemary Hulce Pat Morrissey/Havlin Alexis Oneca Carol Peschke |
| Production Manager | Tracy Potter |
| Audio Production | Frank Cesarano |
| Web Master | John Ribeiro |
| Multimedia Project Manager | Marie Philemon |
| Faculty Relations Manager | Melissa Molieri |
| Continuing Education Administrator for Nursing | Julia W Aucoin, DNS, RN-BC, CNE |
| Contact Information | Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com Email: CE@ResearchToPractice.com |
| For CME/CNE Information | |

Copyright © 2011 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the

newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Prostate Cancer™

U P D A T E

Copyright © 2011 Research To Practice.

This activity is supported by educational grants from Amgen Inc,
Astellas Pharma Global Development Inc/Medivation Inc,
Bayer HealthCare Pharmaceuticals, Dendreon Corporation and Sanofi.

Research
To Practice®

Sponsored by Research To Practice.

Last review date: November 2011

Release date: November 2011

Expiration date: November 2012

Estimated time to complete: 2.75 hours